Market Overview

Alexion Announces Data from Four Clinical Trials Demonstrate Clinical Benefits of Soliris

Alexion Pharmaceuticals (NASDAQ: ALXN) today announced that
researchers presented data from four clinical trials, all demonstrating
the clinical benefits of Soliris® (eculizumab) for the
treatment of atypical hemolytic uremic syndrome (aHUS), a genetic,
chronic, ultra-rare disease associated with vital organ failure and
premature death. Soliris is the first and only approved safe and
effective treatment for pediatric and adult patients with aHUS. In two
large, prospective, multinational studies, Soliris inhibited systemic
complement-mediated thrombotic microangiopathy (TMA, the formation of
blood clots in small blood vessels throughout the body) and improved
renal function in both pediatric and adult patients with aHUS.1,2
The data were presented at Kidney Week 2013, the annual meeting of the
American Society of Nephrology

See full press release

Posted-In: News Guidance Contracts Legal Management Global

 

Related Articles (ALXN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters